SCHEMBL29623773

SCHEMBL29623773

CCOC(=O)C=C1C[C@@H](c2ccc(OC)c(OC3CCCC3)c2)CN1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 17/20 0.64
PDE4A P27815 11/20 0.64
PDE4D Q08499 10/20 0.64
PDE4C Q08493 9/20 0.64
CYP3A4 P08684 2/20 0.64
VEGFA P15692 1/20 0.64
ALDH1A1 P00352 1/20 0.64
LMNA P02545 1/20 0.64
CYP1A2 P05177 1/20 0.64
MAPT P10636 1/20 0.64
CYP2C9 P11712 1/20 0.64
ALOX15 P16050 1/20 0.64
CREBBP Q92793 1/20 0.64
KDM4E B2RXH2 1/20 0.64
PDE5A O76074 1/20 0.64
TNF P01375 1/20 0.64
MAPK1 P28482 1/20 0.64
BLM P54132 1/20 0.64
PDE1A P54750 1/20 0.64
PDE1B Q01064 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29623500 1.00 PDE4B (0.64) PDE4BPDE4APDE4DPDE4CCYP3A4
SCHEMBL6053887 1.00 PDE4B (0.64) PDE4BPDE4APDE4DPDE4CCYP3A4
SCHEMBL6053885 1.00 PDE4B (0.64) PDE4BPDE4APDE4DPDE4CCYP3A4
SCHEMBL1134133 1.00 PDE4B (0.64) PDE4BPDE4APDE4DPDE4CCYP3A4
SCHEMBL28352179 1.00 PDE4B (0.64) PDE4BPDE4APDE4DPDE4CCYP3A4
SCHEMBL28332840 0.87 PDE4B (0.71) PDE4BPDE4APDE4DPDE4CCYP3A4
SCHEMBL4373919 0.87 PDE4B (0.71) PDE4BPDE4APDE4DPDE4CCYP3A4
SCHEMBL4373922 0.87 PDE4B (0.71) PDE4BPDE4APDE4DPDE4CCYP3A4
SCHEMBL28332849 0.87 PDE4B (0.71) PDE4BPDE4APDE4DPDE4CCYP3A4
S-Rolipram SCHEMBL5321568 0.79 PDE4A (1.00) PDE4BPDE4APDE4DPDE4CCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731981-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2023-08-22 US disclosed
CN-110713489-B Heteroaryl SYK inhibitors 勃林格殷格翰国际有限公司 2022-05-31 CN disclosed
CN-110183440-B Heteroaryl SYK inhibitors 勃林格殷格翰国际有限公司 2022-04-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731981-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 PDE4B 1481/4885PDE4A 1334/4885PDE4D 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.